Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy. Investigators would like to understand how these treatments control the prostate cancer and look at their short and long term treatment related side effects. The dose of radiation for HDR brachytherapy for this study has been changed since the study started. Other studies using the dose of radiation for HDR brachytherapy that was originally chosen for this study (Arm 2) found that this dose of radiation may be linked to a greater chance of the cancer coming back in the prostate. Therefore since March 2020, for new participants entering the study, a new HDR brachytherapy arm with a higher amount of radiation given over two doses will be tested in this study


Clinical Trial Description

Radiation therapy is an accepted treatment to help manage low and intermediate risk prostate cancer. Radiation therapy can be given using machines that are outside the body (called "image guided external beam radiation therapy") or by brachytherapy, which is a form of radiation therapy where the radiation source is placed directly into the prostate gland near the tumour. The standard or usual treatments for low or intermediate risk prostate cancer are low dose-rate (LDR) brachytherapy which involves placing radioactive seeds in the prostate which deliver radiation over several months, image guided external beam radiation therapy (IGRT), or IGRT plus high dose-rate (HDR) brachytherapy boost. High Dose-Rate (HDR) brachytherapy is another type of brachytherapy which delivers a high dose of radiation to the tumour over a period of minutes. The radiation is delivered under computer control through flexible needles, which are temporarily inserted into the prostate. This form of radiotherapy targets cancer cells within the prostate gland. HDR brachytherapy is another type of radiotherapy for prostate cancer that has the potential to help target your cancer more accurately while causing fewer side effects compared with standard radiation therapy. HDR brachytherapy is an option for treatment in some hospitals now but the best dose of radiation is still unknown. This study is testing a new dose of radiation for HDR brachytherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02960087
Study type Interventional
Source Canadian Cancer Trials Group
Contact Wendy Parulekar
Phone 613-533-6430
Email wparulekar@ctg.queensu.ca
Status Recruiting
Phase N/A
Start date March 6, 2017
Completion date March 31, 2029

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04457232 - Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation Phase 1
Active, not recruiting NCT03661437 - Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy Early Phase 1
Completed NCT02337465 - KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer N/A
Completed NCT03013413 - Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy N/A
Recruiting NCT06037863 - Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial N/A
Active, not recruiting NCT03580499 - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy N/A
Completed NCT03326440 - Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer N/A
Recruiting NCT04597359 - To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Phase 2
Active, not recruiting NCT03263650 - Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Phase 2
Active, not recruiting NCT04600336 - Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Phase 2
Active, not recruiting NCT04299620 - Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy N/A
Completed NCT04976257 - Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Early Phase 1
Completed NCT02957981 - The Genetic Education for Men Trial: Web-Based Education vs. Standard Care N/A
Withdrawn NCT03408561 - Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer N/A
Enrolling by invitation NCT06347809 - DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
Enrolling by invitation NCT04254133 - Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
Recruiting NCT05519878 - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers N/A
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT01497431 - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants Phase 1
Active, not recruiting NCT00002540 - Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) N/A